# EDGAR Filing Document

**Accession Number:** 0001176309
**File Stem:** 0001213900-25-081720
**Filing Date:** 2025-8
**Character Count:** 7947
**Document Hash:** db76311594591e920efc73062fe9d329
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-081720.hdr.sgml**: 20250828

**ACCESSION NUMBER**: 0001213900-25-081720

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250828

**DATE AS OF CHANGE**: 20250828

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ORAMED PHARMACEUTICALS INC.
- **CENTRAL INDEX KEY:** 0001176309
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 980376008
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-79895
- **FILM NUMBER:** 251273211

**BUSINESS ADDRESS:**
- **STREET 1:** 1185 AVENUE OF THE AMERICAS, 3RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
- **BUSINESS PHONE:** 646-844-1164

**MAIL ADDRESS:**
- **STREET 1:** 1185 AVENUE OF THE AMERICAS, 3RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Integrated Security Technologies, Inc.
- **DATE OF NAME CHANGE:** 20040614

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IGUANA VENTURES LTD
- **DATE OF NAME CHANGE:** 20020625
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** KIDRON NADAV
- **CENTRAL INDEX KEY:** 0001351779

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 142 W. 57TH ST.
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**ORAMED PHARMACEUTICALS INC.**

*(Name of Issuer)*

**Common Stock par value $0.012 per share**

*(Title of Class of Securities)*

**68403P203**

*(CUSIP Number)*

**Nadav Kidron**<br>c/o Oramed Pharmaceuticals Inc.<br>1185 Avenue of the Americas, Third Floor<br>New York NY 10036<br>(844) 967-2633

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**02/11/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **68403P203** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Nadav Kidron** | Name of reporting person<br>**Nadav Kidron** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**L3** | Citizenship or place of organization<br>**L3** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**2898126.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**218603.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**2898126.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**3116729.00** | Aggregate amount beneficially owned by each reporting person<br>**3116729.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**7.6%** | Percent of class represented by amount in Row (11)<br>**7.6%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** (1) Includes 762,750   shares of Common Stock issuable upon the exercise of outstanding stock options that are exercisable or issuable within 60 days of February 11, 2025, 63,541 restricted stock units ("RSUs") that shall vest within 60 days of February 11, 2025 and 73,500 RSUs that were vested but not yet issued.

(2) Consists of 218,603 shares of Common Stock held by Xiaopeng Li, a former director of the Company.

(3) Based upon 41,003,600 shares of Common Stock issued and outstanding as of August 12, 2025, as reported in Issuer's Quarterly Report on Form 10-Q filed on August 14, 2025. The amount of additional shares of Common Stock that Mr. Kidron has the right to acquire within 60 days of February 11, 2025 (137,041 shares) are deemed to be outstanding for purposes of calculating his beneficial ownership percentage.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock par value $0.012 per share

**(b) Name of Issuer:**
ORAMED PHARMACEUTICALS INC.

**(c) Address of Issuer's Principal Executive Offices:**
1185 Avenue of the Americas, Third Floor, New York, NY, 10036

This amendment No. 1 ("Amendment No. 1"), which amends  the Schedule 13D originally filed with the Securities and Exchange Commission on March 22, 2024 (the "Original Schedule 13D"), relates to the common stock, par value $0.012 per share, ("Common Stock") of Oramed Pharmaceuticals Inc., a company incorporated in the state of Delaware (the "Issuer" or "Company"). Except as set forth herein, the Original Schedule 13D, as amended prior to this Amendment No. 1, is unmodified and remains in full force and effect. The principal executive offices of the Issuer are located at 1185 Avenue of the Americas, Third Floor, New York, NY 10036.

**Item 4. Purpose of Transaction**

This item is not being amended by this Amendment No. 1.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The information provided herein is based upon 41,003,600 shares of Common Stock issued and outstanding as of August 12, 2025, as reported in Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 14, 2025.

(a), (b) See the responses (and footnotes) to Items 7 through 11 and 13 in the table on page 2 above.

**(b)**
The aggregate number of shares of Common Stock of the Issuer beneficially owned by the Reporting Person is 3,116,729, which represents approximately 7.6% of the aggregate number of shares of Common Stock issued and outstanding and acquirable by the Reporting Person upon the exercise of options to purchase shares of the Common Stock and vested RSUs. This includes: 1,998,335 shares of Common Stock which were acquired directly by the Reporting Person from time to time, 762,750 shares of Common Stock of the Issuer currently exercisable or exercisable within 60 days of February 11, 2025, 63,541 RSUs that shall vest within 60 days of February 11, 2025, 73,500 RSU that were vested but not yet issued, and 218,603 shares of Common Stock that are held by Ms. Li.

The Reporting Person has the sole power to vote or direct the vote, and to dispose or direct the disposition, of 2,898,126 shares of Common Stock of the Issuer. The Reporting Person has shared power, together with Ms. Li, to vote or direct the vote of 218,603 shares of Common Stock of the Issuer.

**(c)**
None.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

This item is not being amended by this Amendment No. 1.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Nadav Kidron

**Signature:** /s/ Nadav Kidron

**Name/Title:** NADAV KIDRON

**Date:** 08/28/2025